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Abstract
Increasing epidemiological evidence suggests independent associations between psoriasis and
cardiovascular and metabolic disease. Our objective was to test the hypothesis that directly-
assessed psoriasis severity relates to the prevalence of metabolic syndrome and its components.
Population-based, cross-sectional study using computerized medical records from The Health
Improvement Network Study population included individuals aged 45-65 years with psoriasis and
practice-matched controls. Psoriasis diagnosis and extent were determined using provider-based
questionnaires. Metabolic syndrome was defined using National Cholesterol Education Program
(NCEP) Adult Treatment Panel (ATP) III criteria.
44,715 individuals were included: 4,065 with psoriasis and 40,650 controls. 2,044 participants had
mild psoriasis (≤2% body surface area (BSA)), 1,377 had moderate (3-10% BSA), and 475 had
severe psoriasis (>10% BSA). Psoriasis was associated with metabolic syndrome, adjusted odds
ratio (OR) 1.41 (95% CI 1.31-1.51), varying in a “dose-response” manner, from mild (adj. OR
1.22, 95% CI 1.11-1.35) to severe psoriasis (adj. OR 1.98, 95% CI 1.62-2.43).
Psoriasis is associated with metabolic syndrome and the association increases with increasing
disease severity. Furthermore, associations with obesity, hypertriglyceridemia and hyperglycemia
increase with increasing disease severity independent of other metabolic syndrome components.
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These findings suggest that screening for metabolic disease should be considered for psoriasis,
especially when extensive.
Introduction
The metabolic syndrome is a clustering of cardiovascular risk factors, specifically obesity,
hypertension, dyslipidemia and insulin resistance (Eckel et al., 2005), which has been
associated with increased risk of cardiovascular disease (CVD) beyond traditional risk
factors (Mente et al., 2010). The prevalence of metabolic syndrome is increasing in the
United States (US) (Ford et al., 2002) and Europe in part paralleling the rising prevalence of
obesity worldwide (Mente et al., 2010; Mokdad et al., 2003). Systemic inflammation is
associated with metabolic syndrome, with T helper cell type 1 (Th-1)pro-inflammatory
cytokines such as tumor necrosis factor α and non-specific measures of inflammation such
as C reactive protein levels being elevated compared to those without the metabolic
syndrome (Lakka et al., 2002). However, there is a limited understanding of the relationship
between chronic inflammatory diseases and the prevalence of metabolic syndrome.
Psoriasis is the most common Th-1 inflammatory disease, affecting more than 125 million
people worldwide (National Psoriasis Foundation). The severity of psoriasis in the general
population is variable, with most patients having mild disease (Kurd and Gelfand, 2009)
defined as involving ≤ 2% body surface area. Epidemiological evidence suggests that
psoriasis is associated with an increased frequency of cardiovascular risk factors and adverse
cardiovascular outcomes including myocardial infarction (Gelfand et al., 2006), stroke
(Gelfand et al., 2009) and cardiovascular death (Mehta et al., 2009). Psoriasis, especially if
severe, may be a risk factor for atherosclerotic CVD, beyond traditional risk factors
(Gelfand et al., 2009; Gelfand et al., 2006; Mehta et al., 2009). Moreover, patients with
severe psoriasis die approximately 5 years younger than patients without psoriasis, with
cardiovascular death being the most common cause of excess mortality in these patients
(Abuabara et al., 2010). Mechanistic studies of the metabolic syndrome (Shah et al., 2009)
and insulin resistance (Mehta et al., 2010) suggest that chronic Th-1 inflammation that
characterizes psoriasis, metabolic syndrome, diabetes and CVD may in part explain the
association of these phenotypically distinct diseases.
A number of small, epidemiological studies have reported associations between psoriasis
and metabolic syndrome (Al-Mutairi et al., 2010; Azfar and Gelfand, 2008; Gisondi and
Girolomoni, 2009; Mebazaa et al., 2010), however, population-based data in which severity
of psoriasis is objectively determined and individual components of metabolic syndrome are
directly measured are lacking (Augustin et al., 2010). Our objective therefore was to
examine whether there is an association between psoriasis and the metabolic syndrome in a
broadly representative population of patients. We also investigate whether the degree of
association varies by extent of skin involvement with psoriasis.
Results
Table 1 describes the demographics of the study population. At the end of the survey
collection period 4,634 of 4,900 provider-based surveys were completed giving a response
rate of 95%. Our cohort included 4,065 people with confirmed psoriasis and 40650 matched
controls. The mean age of psoriasis patients was 1.2 years older than controls (p<0.001) and
51% of psoriasis patients were male compared to 48% of controls (p<0.001). 2,044 (53%)
participants had mild psoriasis (≤2% body surface area (BSA)), 1,377 (35%) had moderate
disease (3-10% BSA), and 475 (12%) had severe psoriasis (>10% BSA). Information on
body mass index, blood pressure, HDL, glucose and triglycerides was available for 41,249
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(92%), 44,019 (98%), 25234 (56%), 26,144 (64%) and 25,067 (56%) of patients,
respectively (Table 2). The availability of these variables was similar in patients with and
without psoriasis.
Metabolic syndrome was identified in 34% of participants with psoriasis compared to 26%
of controls, odds ratio (OR) 1.50 (95% confidence interval (CI) 1.40-1.61). This association
persisted after adjusting for age, gender and follow up, adjusted (adj.) OR 1.41 (95% CI
1.31-1.51). Adjusting for smoking and social class did not change study findings and these
were not retained in the final model. Psoriasis severity affected the degree of association,
with metabolic syndrome seen in 32% with mild disease (adj. OR 1.22, 95% CI 1.11-1.35),
36% with moderate disease (adj. OR 1.56, 95% CI 1.38-1.76) and 40% of those with severe
psoriasis (adj. OR 1.98, 95% CI 1.62-2.43). Modest but statistically significant interactions
were detected between psoriasis and age and between psoriasis and sex whereby the odds
ratio of metabolic syndrome and psoriasis was slightly higher in younger age groups and in
women (data not shown).
Studying the components of metabolic syndrome, the following factors were more common
in psoriasis patients than in controls: obesity in 38% vs. 31% (OR 1.38, 95% CI 1.29-1.48),
raised triglycerides in 36% vs. 28% (OR 1.49, 95% CI 1.39-1.60), diagnosed hypertension in
31% vs. 28% (OR 1.20, 95% CI 1.11-12.9) and raised glucose in 22% vs. 16% (OR 1.44,
95% CI 1.33-1.56) (Table 2).
In the fully adjusted model to understand which components of the metabolic syndrome
were associated with psoriasis after adjusting for other elements of metabolic syndrome and
age, gender and duration of follow up, the strongest association between a component of the
metabolic syndrome and psoriasis was with obesity, adj. OR 1.25 (95% CI 1.16-1.34). The
association with obesity demonstrated a dose-response with a 14% increase in obesity with
mild psoriasis, adj. OR 1.14 (95% CI 1.03-1.27), 34% increase in obesity with moderate
psoriasis, adj. OR 1.34 (95% CI 1.18-1.53), increasing to a 66% increased odds of being
obese in those with severe psoriasis, adj. OR 1.66 (95% CI 1.33-2.07) (Table 3).
Hypertriglyceridemia and hyperglycemia showed similar dose-response relationships with
severity of psoriasis. There was a 20% increased odds of having raised triglycerides in
individuals with psoriasis overall independent of obesity, adj. OR 1.20 (95% CI 1.10-1.31).
This association also demonstrated an increase from mild psoriasis where the odds of raised
triglycerides was 10% (adj. OR 1.10, 95% CI 0.98-1.25) to a 46% increase in those with
severe psoriasis, adj. OR 1.46 (95% CI 1.13-1.88). Raised glucose was also associated with
psoriasis independent of obesity, with a 16% increased odds of raised glucose overall, adj.
OR 1.16 (95% CI 1.06-1.27) with the association strongest in the group with the most
extensive disease (Table 3).
Sensitivity analysis using revised ATP III, International Diabetes Federation (IDF) criteria
or limiting lab values to the first or most recent observation and excluding individuals on
psoriasis treatments known to impact components of metabolic syndrome, e.g. ciclosporin or
acitretin did not significantly change study conclusions (data not shown).
Discussion
Psoriasis is associated with the metabolic syndrome in a “dose-response” fashion, with a
22% increase in the odds of metabolic syndrome in mild psoriasis, 56% increase in moderate
disease, and a 98% increase in those with severe psoriasis. In a fully adjusted model looking
at associations between factors comprising the metabolic syndrome and psoriasis after
adjusting for other components, independent associations were seen between psoriasis and
Langan et al. Page 3
J Invest Dermatol. Author manuscript; available in PMC 2012 September 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
obesity (25% increased odds), raised triglycerides (20% increased odds) and raised serum
glucose (16% increased odds in a “dose-response fashion” from mild to severe psoriasis.
Strengths of this investigation are that it is a large population-based study with a population
broadly representative of the UK population aged 45-65 years, which minimizes selection
bias and increases the external validity (i.e., generalizability) of the findings. The “dose
response” association detected provides compelling evidence for an association between
psoriasis and metabolic syndrome. Study findings were based on laboratory values and
objectively measured disease extent which allowed observation of novel findings.
Observational study designs are associated with a number of limitations. These include the
cross-sectional nature of this study which does not allow us to determine which developed
first, psoriasis or the metabolic syndrome. Secondly, we cannot be certain that psoriasis
caused the metabolic syndrome; factors including diet, physical inactivity, alcohol or genetic
predisposition which have not been evaluated in this study may be acting as confounding or
effect modifying factors in this relationship (Davidovici et al., 2010) leading to the
possibility of residual confounding. In terms of information bias, two aspects of this study
make this an unlikely explanation for the findings: firstly, laboratory and clinical values
were recorded at similar rates in psoriasis patients and controls as part of routine medical
care by general practitioners unaware of the hypothesis under study, and secondly, the
persistence of the study findings in the sensitivity analysis restricting to the first laboratory
or clinical value per person. Disease severity was determined by asking the GPs to rate the
extent of skin involvement with psoriasis into simple discreet categories
“Disease severity was determined by asking the GPs to rate the extent of skin involvement
with psoriasis into simple discreet categories. While previous studies have suggested that
UK GPs are reasonably accurate in terms of diagnosing psoriasis (Basarab, et al) direct data
on the accuracy of GP assessment of extent of skin involvement with psoriasis is not, to our
knowledge, available. We have previously demonstrated “construct validity” of this
approach in that patients rated by GPs as having higher BSA categories are more likely to
require frequent visits for psoriasis and require systemic therapy specific for psoriasis or
phototherapy (Seminara et al., 2010). Moreover, we used the same categories used in
epidemiological studies conducted by NHANES and NPF in which patients are asked to rate
their degree of skin involvement with psoriasis suggesting that this approach is acceptable
(ie. “face” validity). (Dommasch et al., 2009; Krueger et al., 2001; Seminara et al., 2010).
Moreover, these data represent “real world” data where extent of psoriasis has been assessed
by hundreds of GPs around the UK and resulted in discrimination of the prevalence of
metabolic disorders based upon these clinical assessments, demonstrating the usefulness of
this approach. Nevertheless, our findings are subject to a form of error (i.e. misclassification
of extent of skin involvement) which would be expected to be non-differential and thus bias
towards the null. General practitioners were asked to assess the body surface area of
involvement the patient typically demonstrates; this measure may not be stable over time,
although a previous large cohort study demonstrated that despite various therapeutic
interventions, the severity of psoriasis for individuals did not generally change over time.
(Nijsten et al., 2007)
This study significantly advances the existing literature looking at psoriasis and the
metabolic syndrome as this is the first population-based study to use objective measures of
psoriasis severity, direct measurement of the components of metabolic syndrome and
standard criteria for diagnosis of metabolic syndrome. Of special interest is the clear “dose
response” relationship between psoriasis severity and the metabolic syndrome. No previous
study has to our knowledge shown a directional increase in the association with raised
triglycerides and increasing psoriasis severity independent of the effects of obesity. The
consistency with other study findings (Al-Mutairi et al., 2010; Augustin et al., 2010;
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Gisondi and Girolomoni, 2009; Love et al., 2010; Mebazaa et al., 2010), presence of a “dose
response” relationship, strong associations and biological plausibility support some
causality, but further mechanistic and longitudinal studies are required (Rothman and
Greenland, 2005).
A possible biologic mechanism which may account for this association is that the
proinflammatory state associated with psoriasis acts as a central driving force for
development of the metabolic syndrome. In psoriasis patients, Th1 inflammatory cytokines
e.g. TNF-α, IL-1 and IL-6, are increased in skin and blood (Azfar and Gelfand, 2008). These
inflammatory mediators may have a range of effects on insulin signalling, lipid metabolism
and adipogenesis. Additionally, inflammation-induced insulin resistance may lead to
development of a systemic insulin resistant state (Mehta et al., 2010)Further mechanistic
studies will be needed to test this hypothesis.
Study findings demonstrate a strong association between psoriasis and the metabolic
syndrome, with increasing psoriasis severity being associated with increasing odds of
metabolic syndrome. Increased odds of raised triglycerides and serum glucose were seen in
individuals with psoriasis independent of the effects of obesity. The results of this study
firmly establish that metabolic syndrome is an important comorbidity with psoriasis and that
vigilance and enhanced screening may be important in psoriasis patients, particularly those
with severe disease. Examining the components of metabolic syndrome associated with
psoriasis, weight reduction is clearly a key step to prevent CVD; however our findings also
show that screening for the other components of metabolic syndrome, particularly
hypertriglyceridemia and raised glucose as these tests are more likely to be abnormal in
patients with psoriasis independent of traditional risk factors (such as obesity). Small
increases in the individual components of metabolic syndrome have lead to an 8% absolute
increase in the prevalence of metabolic syndrome overall and a 14% increase in those with
severe psoriasis. Further prospective studies are required to determine the directionality of
the association between psoriasis and metabolic syndrome and to study other unexplored
confounders including diet, physical activity, alcohol and genetic factors which may be
important residual confounders in this relationship.
Materials and methods
Study design
We conducted a cross-sectional study utilizing The Health Improvement Network (THIN).
Study population
THIN is a computerised longitudinal general practice database with demographic data
similar to the general United Kingdom (UK) population. THIN has anonymised medical
record data on 3.4 million “active” patients followed for a cumulative 50 million person
years and is broadly representative of the UK population. The THIN database contains
demographic details, diagnoses, laboratory results, and prescriptions recorded by general
practitioners (GPs), the gatekeepers for medical care in the UK. The version of THIN we
used contained data from 413 general practices that use the “In Practice Vision” software. A
number of studies have confirmed that THIN data are highly accurate making it ideal for use
in epidemiological research (Lewis et al., 2007; Seminara et al., 2010). The cohort was
identified from individuals aged 45 to 64 years with at least one psoriasis Read code (using a
previously validated coding algorithm (Seminara et al., 2010)) in the two years before the
survey. Patients were required to be registered with a general practice contributing actively
to Additional Information Services (AIS). AIS practices have an agreement to respond to
questionnaires; 55% (n=228) of THIN practices were AIS active at the time of sampling.
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4,900 eligible patients with psoriasis diagnostic codes were randomly sampled, and
questionnaires were sent to their general practitioners through AIS to verify the presence of
psoriasis and extent of disease. Up to 10 controls aged 45 to 64 years were randomly
matched to each psoriasis patient based on practice; similar to cases, controls needed to be
alive and actively registered with at least one general practitioner visit within 2 years at the
time of sampling
Outcomes
Patients were defined as having psoriasis if their diagnosis was confirmed by a questionnaire
completed by their general practitioner. The questionnaire also determined the severity of
psoriasis, namely mild psoriasis (<2% body surface area), moderate psoriasis (3-10% body
surface area) and severe psoriasis (>10% body surface area). This approach has been
previously well accepted (Feldman, 2004). Cardiovascular risk factors, specifically body
mass index (BMI) calculated using standard formulation (overweight was defined as BMI
≥25 kg/m2 and <30 kg/m2, obese was defined as ≥30 kg/m2), hypertension,
hyperlipidaemia, smoking and diabetes mellitus, were identified by the presence of
diagnostic Read codes and additional recording and laboratory values in the Additional
Health Details portion of the database.
Subjects were defined as having metabolic syndrome using the National Cholesterol
Education Program (NCEP) Adult Treatment Panel (ATP) III diagnostic criteria(Expert
Panel on Detection, 2001). Using NCEP criteria, a person with metabolic syndrome fulfills 3
or more of the following criteria: central obesity (determined by a BMI≥30 in THIN),
hypertriglyceridaemia ≥1.7mmol/l, low HDL cholesterol (in men <1.03mmol/l and in
women <1.29mmol/l), high blood pressure ≥130/85mmHg and high fasting glucose
≥6.1mmol/l. Time-varying variables were dealt with by selecting the maximum laboratory
value or clinical measurement and using the most recent value for body mass index.
Measurement of conditions occurred from the patients start date (defined as the latest of the
Vision software or computerisation in the practice and registration dates of the patient) while
the end of the study was defined as earliest date of transfer out, death or end of the study
period in February 2009.
Study size
We calculated that a sample size of 4,900 would yield 4,190 patients which would be
sufficient to detect increased relative risks of 1.14 for a BMI of 25 or greater, 1.37 for
hypertension, 1.71 for hyperlipidaemia and 2.0 for diabetes mellitus with 80% power
respectively assuming a two-sided test and a significance level of 0.05 and we were satisfied
that such differences would be clinically meaningful.
Statistical methods
Odds ratios (OR) and 95% confidence intervals (CI) for the association between psoriasis
overall and by psoriasis extent were calculated using conditional logistic regression.
Multiplicative interaction terms were fitted to assess effect modification by age and sex.
Adjusted ORs were determined adjusting for confounders including age, sex and duration of
follow up time in THIN. Other possible confounders which were explored included smoking
and social class, measured using Townsend scores(Phillimore et al., 1994). Further analyses
were undertaken of the association between psoriasis and disease extent and the components
of metabolic syndrome to ensure that findings were not explained by individual components
such as obesity. Sensitivity analyses were undertaken using the revised NCEP ATP III
definition (glucose cut point >5.6mmol/l) and the International Diabetes Federation (IDF)
definitions of metabolic syndrome (Zimmet et al., 2005). Sensitivity analyses were also
carried out using only the first and most recent laboratory value for each individual and in
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patients who did not receive psoriasis treatments that may affect blood pressure and lipids
(i.e. ciclosporin or acitretin). All analyses were carried out in Stata SE10 (Stata Corporation,
College Station, TX, USA)
Ethics
This study was approved by the University of Pennsylvania institutional review board and
the Cambridgeshire Research Ethics Committee and was funded by the National Heart Lung
and Blood Institute of the NIH.
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Abbreviations
NCEP National Cholesterol Education Program
ATP Adult Treatment Panel
BSA body surface area
OR odds ratio
CI 95% confidence interval
CVD cardiovascular disease
Th-1 T helper cell type 1
THIN The Health Improvement Network
AIS Additional Information Services
BMI body mass index
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Table 1
Demographic details of cohort
Characteristic No Psoriasis (n, %) Psoriasis (n, %)
Overall 40,650 (90.9) 4,065 (9.1)
By psoriasis extent
≤2% N/A 2044 (52.5)
3-10% N/A 1377 (35.3)
>10% N/A 475 (12.2)
Gender
Men 19304 (47.5) 2081 (51.2)
Women 21346 (52.5) 1984 (48.8)
Age group (years)
<50 13348 (32.8) 1082 (26.6)
50-54 10040 (24.7) 1000 (24.6)
55-59 9271 (22.8) 945 (23.3)
>60 7991 (19.7) 1038 (25.5)
Median (Interquartile range measurements) of maximum individual
Body mass index (kg/m2) 27.1 (23.7-31.2) 28.4 (24.9-32.9)
Systolic blood pressure (mmHg) 144 (130-162) 149 (135-168)
Diastolic blood pressure (mmHg) 90 (80-100) 90 (82-100)
Triglyceride level (mmol/l) 1.7 (1.1-2.5) 1.9 (1.2-2.8)
Cholesterol level (mmol/l) 5.8 (5.1-6.7) 6.0 (5.2-6.8)
High density lipoprotein (mmol/l) 1.5 (1.2-1.8) 1.4 (1.2-1.7)
Low density lipoprotein (mmol/l) 3.6 (2.9-4.3) 3.7 (3.0-4.3)
Glucose (mmol/l) 5.4 (4.9-6.4) 5.6 (4.9-6.6)
C reactive protein (mg/l) 5 (3-10) 7 (4-13)
Metabolic syndrome n (%) 10515 (25.9) 1389 (34.2)
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